Carbapenem-Resistant Enterobacteriaceae

CRE Basics - Superbugs Unmasked

• Carbapenem-Resistant Enterobacteriaceae (CRE): Gram-negative bacteria resistant to most carbapenem antibiotics.
• Dubbed "superbugs" due to extensive drug resistance, leading to high mortality (up to 50%) and limited treatment options.
• Key pathogens: Klebsiella pneumoniae, Escherichia coli.
• Resistance mechanisms are diverse, often plasmid-mediated, facilitating rapid spread.
• Primarily healthcare-associated infections (HAIs); risk factors include ICU stay, catheters, prior antibiotic use.

  ⭐ CRE are defined by resistance to at least one carbapenem (e.g., meropenem, imipenem) OR production of a carbapenemase enzyme.

Resistance Secrets - Carbapenem Dodge

• Primary Weapon: Carbapenemases (Enzymatic hydrolysis of carbapenems)
  • Serine carbapenemases: KPC (Klebsiella pneumoniae carbapenemase) - Ambler Class A
  • Metallo-β-lactamases (MBLs): NDM (New Delhi MBL), VIM, IMP - Ambler Class B (require $Zn^{2+}$)
  • OXA-type carbapenemases: OXA-48-like - Ambler Class D (weak hydrolysis, often needs other mechanisms)
• Secondary Defenses: (Often contribute synergistically)
  • ↑ Efflux pumps: Drug expulsion from cell.
  • ↓ Porin channels (e.g., OmpK35/36 in K. pneumoniae): Reduced drug entry.
  • ESBL/AmpC hyperproduction + porin loss: Combined effect enhances resistance.

⭐ NDM-1 (New Delhi Metallo-beta-lactamase-1) is a prominent MBL, conferring broad β-lactam resistance (sparing aztreonam in some NDM producers without other resistance mechanisms).

📌 Mnemonic for major carbapenemases: "King Neptune's Ocean Vortex Islands" (KPC, NDM, OXA, VIM, IMP).

Enzyme Villains - Carbapenemase Crew

Major carbapenem-hydrolyzing enzymes responsible for CRE:

• KPC (Klebsiella pneumoniae Carbapenemase)
  • Ambler Class A serine carbapenemase.
  • Plasmid-mediated, efficient hydrolysis. Global spread.
• NDM (New Delhi Metallo-β-lactamase)
  • Ambler Class B Metallo-β-lactamase (MBL).
  • Zinc-dependent. 📌 New Delhi Metal.
  • High prevalence in India; broad spectrum activity.
• OXA-48-like (Oxacillinase)
  • Ambler Class D serine carbapenemase.
  • Weaker carbapenem hydrolysis; often requires high expression or other mechanisms.
• VIM & IMP (Verona Integron-encoded & Imipenemase)
  • Ambler Class B MBLs.
  • Zinc-dependent; found globally.

⭐ NDM-1 was first identified in 2008 in a Swedish patient of Indian origin who had received medical care in New Delhi, India.

Detection & Defense - CRE Combat Plan

• Detection Strategy
  • Screening: Rectal swabs for high-risk patients (ICU, prolonged hospitalization, prior broad-spectrum antibiotics).
  • Phenotypic Tests:
    • mCIM/eCIM: Differentiates KPC/OXA-48 like (serine carbapenemases) from MBLs.
    • Carba NP test: Rapid, colorimetric detection of carbapenemase activity.
  • Genotypic Tests: PCR for common carbapenemase genes (e.g., $blaKPC$, $blaNDM$, $blaOXA-48-like$, $blaVIM$, $blaIMP$).

    ⭐ The modified Carbapenem Inactivation Method (mCIM) and EDTA-mCIM (eCIM) are crucial for differentiating metallo-β-lactamase (MBL) production from serine carbapenemase production.

• Common Infections Caused
  • Pneumonia (especially Ventilator-Associated Pneumonia - VAP).
  • Bacteremia and sepsis.
  • Complicated Urinary Tract Infections (cUTIs).
  • Intra-abdominal infections.
• Treatment Arsenal (Combination Therapy Often Essential)
  • Newer β-lactam/β-lactamase inhibitors: Ceftazidime-avibactam, Meropenem-vaborbactam, Imipenem-cilastatin-relebactam.
  • Siderophore cephalosporin: Cefiderocol.
  • Older agents (use with caution, guided by susceptibility): Polymyxins (Colistin, Polymyxin B), Tigecycline (⚠️ black box warning for ↑mortality), Fosfomycin (especially for cUTIs), Aminoglycosides.
• Prevention & Control (IPC Pillars - 📌 SHIELD Mnemonic)
  • Surveillance & Screening (active).
  • Hand Hygiene (rigorous).
  • Isolation/Contact Precautions.
  • Environmental Disinfection.
  • Limit Devices/Stay.
  • Drug Stewardship (ASP).

High‑Yield Points - ⚡ Biggest Takeaways

• CRE are Enterobacteriaceae resistant to most carbapenems, posing a severe public health threat.
• Key mechanisms include carbapenemase production (e.g., KPC, NDM, OXA-48).
• NDM-1 is a major concern, especially in the Indian subcontinent.
• Associated with high mortality rates and limited therapeutic options.
• Infection control measures are crucial to prevent spread in healthcare settings.
• Diagnosis involves phenotypic and molecular tests to detect resistance.
• Treatment often requires combination therapy or newer agents like ceftazidime-avibactam.